The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Opioid dependence treatment: options in pharmacotherapy
Open accessAbstract
The development of effective treatments for opioid dependence is of great importance given the devastating consequences of the disease. Pharmacotherapies for opioid addiction include opioid agonists, partial agonists, opioid antagonists, and alpha-2-adrenergic agonists, which are targeted toward either detoxification or long-term agonist maintenance. Agonist maintenance therapy is currently the recommended treatment for opioid dependence due to its superior outcomes relative to detoxification. Detoxification protocols have limited long-term efficacy, and patient discomfort remains a significant therapy challenge. Buprenorphine's effectiveness relative to methadone remains a controversy and may be most appropriate for patients in need of low doses of agonist treatment. Buprenorphine appears superior to alpha-2 agonists, however, and office-based treatment with buprenorphine in the USA is gaining support. Studies of sustained-release formulations of naltrexone suggest improved effectiveness for retention and sustained abstinence; however, randomized clinical trials are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · cited 2×
“…of prescription only users, 30% of heroin only, 38% who used both 41% overall; 75% of prescription only users, 52% of heroin only, 48% who used both Fudala et al., 2003 Bup only, Bup + Naloxone, Placebo 4 weeks 82% 75% 69% 21% 18% 6% Mintzer et al., 2007 None 6 months 100% 54% O’Connor et al.,…”
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Kimber, J., Breen, C., & Davoli, M. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub3 · Cited by 501
Kakko, J., Svanborg, K. D., Kreek, M. J., & Heilig, M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12600-1 · Cited by 466
Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial
Ling, W., Charuvastra, C., Collins, J. F., Batki, S., Brown, L. S., Kintaudi, P., Wesson, D. R., Mcnicholas, L., Tusel, D. J., Malkerneker, U., et al. (1998) · Addiction · doi:10.1046/j.1360-0443.1998.9344753.x · Cited by 402
Acute administration of buprenorphine in humans: partial agonist and blockade effects.
Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10510-7 · Cited by 283
Depot naltrexone: long-lasting antagonism of the effects of heroin in humans
Comer, S., Collins, E., Kleber, H., Nuwayser, E., Kerrigan, J., & Fischman, M. (2002) · Psychopharmacology · doi:10.1007/s002130100909 · Cited by 175
Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Settings
Mintzer, I. L., Eisenberg, M., Terra, M., MacVane, C., Himmelstein, D. U., & Woolhandler, S. (2007) · The Annals of Family Medicine · doi:10.1370/afm.665 · Cited by 117
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Gerra, G., Fantoma, A., & Zaimovic, A. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060835 · Cited by 106
Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy
HALLINAN, R., BYRNE, A., AMIN, J., & DORE, G. J. (2005) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2005.03882.x · Cited by 56 · cited 1×
“Failure to prescribe naltrexone to patients with less elevation in LFTs is unfortunate, as a significant proportion of the opiate-using population has liver disease such as hepatitis B or C [103,104].”
Cited by
Retention in medication-assisted treatment for opiate dependence: A systematic review
Timko, C., Schultz, N. R., Cucciare, M. A., Vittorio, L., & Garrison-Diehn, C. (2016) · Journal of Addictive Diseases · doi:10.1080/10550887.2016.1100960 · Cited by 489
Effects of Schedule I drug laws on neuroscience research and treatment innovation
Nutt, D. J., King, L. A., & Nichols, D. E. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3530 · Cited by 337
Retention of patients in opioid substitution treatment: A systematic review
O’Connor, A. M., Cousins, G., Durand, L., Barry, J., & Boland, F. (2020) · PLOS ONE · doi:10.1371/journal.pone.0232086 · Cited by 298
GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures
Shimada, I., Ueda, T., Kofuku, Y., Eddy, M. T., & Wüthrich, K. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.180 · Cited by 279
The role of the opioid system in decision making and cognitive control: a review
van Steenbergen, H., Eikemo, M., & Leknes, S. (2019) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-019-00710-6 · Cited by 118
Metadata
- Authors
- Stotts, A. L., Dodrill, C. L., & Kosten, T. R.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2009-06-18
- Volume
- 10
- Issue
- 11
- Pages
- 1727-1740
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2150270654
- Cited by
- 222
- References
- 10
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Opioid dependence treatment: options in pharmacotherapy. https://app.cochat.ai/papers/10.1517/14656560903037168
- The paper
- Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009). Opioid dependence treatment: options in pharmacotherapy. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656560903037168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.